Inicio › Síndromes mielodisplásicos › Connecticut
Ensayos clínicos de Síndromes mielodisplásicos en Connecticut
11 estudios sobre Síndromes mielodisplásicos buscan participantes en Connecticut.
Ciudades en Connecticut
Texto oficial del estudio (inglés)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Yale University, New Haven
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05564390A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Yale, New Haven
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT07422480The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
ReclutandoFase 1/2
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Smilow Cancer Hospital at Yale-New Haven, New Haven
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06499285ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Yale University, Yale Cancer Center, New Haven
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06656494Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
- Connecticut Children's Medical Center, Hartford
ReclutandoEstudio observacional
Hasta los 30 · Todos los sexos · Actualizado el 16 jul 2026 · NCT04968834A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, New Haven
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jun 2026 · NCT06847867A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 abr 2026 · NCT04256317Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Yale-New Haven Hospital, New Haven
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 abr 2026 · NCT06419634SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Hartford
- Massive Bio SYNERGY-AI site, Norwalk
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.